Coronavirus (COVID-19) Update - We are open with your safety in mind.
Click here to learn more.
The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) infusion every 4 weeks reduces the frequency of seizures in adult subjects with drug-resistant focal epilepsy.
Biogen MA Inc
Mohamad Koubeissi, MD